These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 36916140)

  • 1. Long-term outcomes of sirolimus treatment for kaposiform hemangioendothelioma: Continuing successes and ongoing challenges.
    Zhou J; Li Y; Qiu T; Gong X; Yang K; Zhang X; Zhang Z; Lan Y; Hu F; Peng Q; Zhang Y; Kong F; Chen S; Ji Y
    Int J Cancer; 2023 Aug; 153(3):600-608. PubMed ID: 36916140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kaposiform haemangioendothelioma: clinical features, complications and risk factors for Kasabach-Merritt phenomenon.
    Ji Y; Yang K; Peng S; Chen S; Xiang B; Xu Z; Li Y; Wang Q; Wang C; Xia C; Li L; Liu X; Lu G; Yang G; Wu H
    Br J Dermatol; 2018 Aug; 179(2):457-463. PubMed ID: 29603128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment experience for different risk groups of Kaposiform hemangioendothelioma.
    Li M; Wang X; Kieran R; Sun ZW; Gong Y; Lei H; Sun B; Xiao L; Wang Y; Wang S; Li Z; Wang L; Lv R; Xue F; Ge J; Dong C; Huo R
    Front Oncol; 2024; 14():1336763. PubMed ID: 38903724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Case of Superficial Kaposiform Hemangioendothelioma Treated with Oral Propranolol Combined with Topical Sirolimus.
    Dang N; Ren Y
    Vasc Health Risk Manag; 2024; 20():251-254. PubMed ID: 38883398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus combined with glucocorticoids in the treatment of Kasabach-Merritt phenomenon in a neonate: A case report.
    Cheng J; Zou Y; Fu R; Jin P; Huang M; Wu Z; Bai H; Huang X; Yuan H
    Medicine (Baltimore); 2024 Apr; 103(14):e37706. PubMed ID: 38579031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost and effectiveness comparison of sirolimus versus standard treatment in Kasabach-Merritt phenomenon: a real-world evidence study in Thailand.
    Tongruang C; Wananukul S; Chatproedprai S; Narkbunnam N; Nitiyarom R; Sirachainan N; Natesirinilkul R; Chaweephisal P; Sosothikul D
    Pediatr Hematol Oncol; 2024 Apr; 41(3):229-239. PubMed ID: 38235681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kaposiform Hemangioendothelioma with Bone Destruction: A 16-Year Follow-Up Cohort Study of the Clinical Characteristics and Prognosis.
    Qiu T; Zhang Z; Liu J; Zhou J; Gong X; Lan Y; Zhang X; Chen S; Ji Y
    J Pediatr Surg; 2024 Apr; 59(4):599-604. PubMed ID: 38158257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus monotherapy for Kasabach-Merritt phenomenon in a neonate; Case report.
    Nakamura S; Ozeki M; Hayashi D; Yasue S; Endo S; Ohnishi H
    Int J Surg Case Rep; 2024 Apr; 117():109497. PubMed ID: 38518465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Xenograft Model of Kaposiform Hemangioendothelioma in Nude Mice Recapitulates Kasabach-Merritt Phenomenon.
    Wang Q; Qiu WW; Li MY; Shen WM; Yuan SM
    Ann Vasc Surg; 2024 Nov; 108():419-425. PubMed ID: 39025210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case report of primary Kaposiform hemangioendothelioma of the humerus.
    Wang Y; He Z; Hao H
    Int J Immunopathol Pharmacol; 2024 Jul; ():3946320241266914. PubMed ID: 39031761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial: Recent advances in childhood vascular tumors.
    Qiu T; Yang K; Ji Y
    Front Oncol; 2024; 14():1465155. PubMed ID: 39119090
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapy with sirolimus in vascular anomalies: the experience of two Italian centers on 14 pediatric patients.
    Neirotti A; Barat V; Coppo P; La Selva R; Manicone R; Cotti R; Sensini M; Mussa A; Gatto M; Farri F; Basso ME; Fagioli F
    Front Pediatr; 2024; 12():1434493. PubMed ID: 39086628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coexistence of kaposiform hemangioendothelioma and capillary malformation: More than a coincidence? Two case reports.
    Gong X; Zhou J; Chen S; Ji Y
    Heliyon; 2024 Apr; 10(7):e28802. PubMed ID: 38576567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and applications of the EOMA spheroid model of Kaposiform hemangioendothelioma.
    Li Y; Zhu X; Li L; Bao C; Liu Q; Zhang N; He Z; Ji Y; Bao J
    J Biol Eng; 2024 Mar; 18(1):21. PubMed ID: 38486263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refractory kaposiform lymphangiomatosis relieved by splenectomy.
    Lan Y; Zhou J; Qiu T; Gong X; Ji Y
    Front Pediatr; 2023; 11():1203336. PubMed ID: 37664553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of age and tumor size on the development of the Kasabach-Merritt phenomenon in patients with kaposiform hemangioendothelioma: a retrospective cohort study.
    Zhou J; Lan Y; Qiu T; Gong X; Zhang Z; He C; Peng Q; Hu F; Zhang X; Lu G; Qiu L; Kong F; Zhang Y; Chen S; Ji Y
    Precis Clin Med; 2023 Jun; 6(2):pbad008. PubMed ID: 37305527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: Kaposiform hemangioendothelioma with PIK3CA mutation successfully treated with sirolimus.
    Wang Z; Yan H; Ma Y; Yao W; Zheng S; Li K
    Front Oncol; 2023; 13():1132702. PubMed ID: 37274236
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.